Healthcare giant Johnson & Johnson (JNJ) on Wednesday announced a proposed Plan of Reorganization, for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.The consensual and Prepackaged Reorganization by its subsidiary, LLT Management LLC is expected to resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States.The Plan provides for a three-month solicitation period during which ovarian claimants would be informed of its terms and would have the opportunity to vote for or against it.

医疗保健巨头强生公司（Johnson&Johnson，JNJ）周三宣布了一项拟议的重组计划，旨在全面最终解决目前和未来所有与卵巢癌有关的索赔，这些索赔是由针对其及其在美国的附属公司的滑石粉美容诉讼引起的。其子公司LLT Management LLC的协商一致和预先包装的重组预计将解决所有针对强生及其在美国的附属公司的未决滑石诉讼的99.75%。该计划规定了为期三个月的征集期，在此期间，卵巢索赔人将被告知其条款，并有机会对其投赞成票或反对票。

Such an opportunity was denied in prior bankruptcy cases. If 75% of claimants vote in favor of the Plan, a Company subsidiary would file a consensual 'prepackaged' Chapter 11 bankruptcy to secure its confirmation.The Plan commits the Company to pay ovarian claimants a present value of approximately $6.475 billion to be paid over 25 years, which is expected to be a far better recovery than the claimants stand to recover at trial..

在之前的破产案件中，这样的机会被剥夺了。如果75%的索赔人投票赞成该计划，公司子公司将提交一份双方同意的“预先打包”的第11章破产申请，以确保其得到确认。该计划承诺该公司将在25年内支付卵巢索赔人约64.75亿美元的现值，预计这将比索赔人在审判中所能获得的收益要好得多。。

To account for the comprehensive resolution of the ovarian claims through the Plan, as well as the other settlements, the company has recorded an incremental charge of approximately $2.7 billion in the first quarter of 2024. The total reserve is approximately $11.0 billion or $13.7 billion nominal payable over 25 years.The company clarified that it would continue to pursue alternative resolution pathways while reiterating that none of the talc-related claims against it have merit.

为了通过该计划全面解决卵巢索赔以及其他结算，该公司在2024年第一季度记录了约27亿美元的增量费用。总准备金约为110亿美元，即25年内名义应付137亿美元。该公司澄清说，它将继续寻求其他解决途径，同时重申，与滑石粉相关的针对它的索赔都没有价值。

For comments and feedback contact: editorial@rttnews.com.

如需评论和反馈，请联系：editorial@rttnews.com.

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股